Table 2.
Cumulative risk for breast, OFP, and all cancers combined prospectively diagnosed during follow-up
| BRCA1/2 mutation status | Study cohort | Cumulative cancer risks* (95% CI) |
||
|---|---|---|---|---|
| Breast† | OFP‡ | All | ||
| Age 30 to 50 years | ||||
| Positive BRCA1/2 | OCS | 0.31 (0.16 to 0.46) | 0.14 (0.02 to 0.26) | 0.42 (0.27 to 0.57) |
| RRSO | 0.20 (0.12 to 0.28) | — | 0.20 (0.13 to 0.27) | |
| BRCA1 | OCS | 0.39 (0.29 to 0.49) | 0.26 (0.16 to 0.36) | 0.54 (0.45 to 0.63) |
| RRSO | 0.26 (0.20 to 0.32) | — | 0.23 (0.18 to 0.28) | |
| BRCA2 | OCS | 0.21 (0.08 to 0.34) | 0 | 0.30 (0.17 to 0.43) |
| RRSO | 0.12 (0.07 to 0.17) | — | 0.16 (0.13 to 0.19) | |
| Negative | OCS | 0.06 (0.02 to 0.11) | 0 | 0.12 (0.06 to 0.18) |
| RRSO | 0.11 (0.00 to 0.22) | — | 0.15 (0.04 to 0.26) | |
| All | OCS | 0.15 (0.08 to 0.22) | 0.03 (0.00 to 0.05) | 0.22 (0.15 to 0.30) |
| RRSO | 0.16 (0.10 to 0.22) | — | 0.17 (0.12 to 0.23) | |
| Age 30 to 70 years | ||||
| Positive BRCA1/2 | OCS | 0.49 (0.24 to 0.75) | 0.27 (0.08 to 0.46) | 0.65 (0.47 to 0.83) |
| RRSO | 0.42 (0.30 to 0.53) | — | 0.44 (0.34 to 0.53) | |
| BRCA1 | OCS | 0.67 (0.46 to 0.88) | 0.45 (0.31 to 0.59) | 0.84 (0.74 to 0.94) |
| RRSO | 0.49 (0.42 to 0.56) | — | 0.46 (0.40 to 0.52) | |
| BRCA2 | OCS | 0.39 (0.20 to 0.58) | 0 | 0.42 (0.27 to 0.55) |
| RRSO | 0.33 (0.24 to 0.42) | — | 0.41 (0.33 to 0.49) | |
| Negative | OCS | 0.21 (0.12 to 0.30) | 0.04 (−0.01 to 0.09) | 0.36 (0.26 to 0.45) |
| RRSO | 0.30 (0.15 to 0.45) | — | 0.44 (0.28 to 0.59) | |
| All | OCS | 0.29 (0.20 to 0.39) | 0.08 (0.02 to 0.13) | 0.44 (0.36 to 0.53) |
| RRSO | 0.35 (0.26 to 0.44) | — | 0.42 (0.34 to 0.51) | |
Cumulative risk denotes an estimate of the pure probability of developing the event over the age ranges specified. CI = confidence interval; OCS = ovarian cancer screening; OFP = ovarian/fallopian tube/peritoneal; RRSO = risk-reducing salpingo-oophorectomy.
Participants with bilateral breast cancer, unilateral breast cancer plus contralateral risk-reducing mastectomy, or bilateral risk-reducing mastectomy prior to enrollment were excluded from the breast cancer risk estimates. Participants who underwent risk-reducing mastectomy during prospective follow-up were censored at the time of risk-reducing surgery.
OFP cancer risk was not estimated for participants who had RRSO (indicated with —).